Prioritising at-risk adults in vaccine coadministration trials
The COVID-19 pandemic reminded us of what vaccines can do to prevent life-threatening diseases.1 Respiratory infections such as influenza, COVID-19, respiratory syncytial virus (RSV), and pneumococcal disease contribute significantly to global morbidity and mortality, especially among older individuals and high-risk groups.2 These respiratory infections are at least in part preventable by vaccination—if the vaccines are ever administered. Suboptimal vaccine coverage in adult groups with high risk of severe disease is a concern, and vaccine coadministration is a practical solution to increase vaccine uptake.
